Column:ÃΤβͤ±¶¶
2018ǯ4·î1Æü¹æ
¡ÖQOL¡×¤ò¹Í¤¨¤ë­¡
·ò¹¯³ØÉô·ò¹¯¥Þ¥Í¥¸¥á¥ó¥È³Ø²Ê¡¡ËÙ±Ûͳµª»Ò ¶µ¼ø

QOL¤ÎÍðÍѤòËɤ°¤Ë¤Ï
³µÇ°¤òÌÀ³Î¤Ë¤·¤ÆÃí°Õ¿¼¤¯À¿¼Â¤Ë


¥¯¥ª¥ê¥Æ¥£¡¦¥ª¥Ö¡¦¥é¥¤¥Õ(Quality of Life:QOL)¤Ï¡¢À¸³è¤Î¼Á¤ÈÌõ¤µ¤ì¤ë¤³¤È¤¬Â¿¤¤¤¬¡¢¤É¤³¤Ç¤âï¤Ë¤Ç¤âÄÌÍѤ¹¤ëÄêµÁ¤È¤Ê¤ë¤È¡¢¤Ê¤«¤Ê¤«Æñ¤·¤¤¡£¤½¤ì¤Ï°ì¤Ä¤Ë¤Ï¡¢¡Ö¥é¥¤¥Õ¡×¤Î1¸ì¤¬¡¢À¸Ì¿¡¦À¸¤­¤ë¤³¤È¡¢À¸³è¡¦Êë¤é¤¹¤³¤È¡¢¤½¤·¤Æ¿ÍÀ¸¡¦À¸³¶¤Ê¤É¿ÍͤʰÕÌ£¤ò»ý¤Ä¤³¤È¤Ë¤è¤ë¡£¤½¤·¤Æ¤â¤¦°ì¤Ä¤Ë¤Ï¡¢¡Ö¥¯¥ª¥ê¥Æ¥£=¼Á¡×¤òÀ¸³è¤ä¿ÍÀ¸¤Ë°ú¤­¤Ä¤±¤Æ¹Í¤¨¤è¤¦¤È¤¹¤ì¤Ð¡¢¿Í¡¹¤ÎÁª¹¥¤ò¹Íθ¤ËÆþ¤ì¤¶¤ë¤òÆÀ¤º¡¢·ë²Ì¤ËÍɤ餮¤¬À¸¤¸¤ë¤³¤È¤â´Ø·¸¤·¤Æ¤¤¤ë¡£¤½¤³¤Ç¡¢¼ÜÅ٤Ȥ·¤ÆQOL¤ò»È¤ª¤¦¤È¤¹¤ë¸¦µæ¼Ô¤¿¤Á¤Ï¡¢¤½¤ÎµÒ´Ñ²½¤È»ØÉ¸²½¤Ë¼è¤êÁȤó¤Ç¤­¤¿¡£
¡¡
¤¿¤È¤¨¤Ð¥¢¥á¥ê¥«¤Î°å³Ø¸¦µæ¼Ô¤Ç¤¢¤ë¥¹¥Ô¥ë¥«¡¼(Spilker,B.)¤Ï¡¢QOL¤Ï¿ÈÂÎŪ¾õÂ֤俴ÍýŪ¾õÂ֤˲䨤ơ¢¼Ò²ñŪ¸òή¤ä·ÐºÑŪ¡¦¿¦¶ÈŪ¾õÂÖ¡¢¤½¤·¤Æ½¡¶µÅª¡¦¼Â¸Ū¾õÂÖ¤Î5¤Ä¤ÎÎΰè¤Ë½¸Ì󤵤졢¤½¤ì¤é¤òÊñ³ç¤¹¤ë¾õÂ֤Ȥ·¤Æ¤ÎQOL¤¬¤¢¤ë¤ÈÄêµÁ¤·¤¿¡£¤·¤«¤·¡¢¼£ÎŸú²Ì¤Î¥¨¥Ó¥Ç¥ó¥¹(evidence:º¬µò¡¦º¬µò¥Ç¡¼¥¿)¤òÌÀ¤é¤«¤Ë¤·¤¿¤¤°åÎŤǤϡ¢¤³¤¦¤·¤¿ÄêµÁ¤Ç¤Ï¥Ñ¥Á¥Ã¤È¤Ï¤Þ¤é¤Ê¤¤¡£¤½¤³¤Ç¡¢QOL¤ò¡¢¼£ÎŤˤè¤Ã¤ÆÄ¾ÀܱƶÁ¤ò¼õ¤±¡¢·ò¹¯¾õÂ֤βþÁ±¤¬¸«¹þ¤Þ¤ì¤ëÈϰϤǤȤ館¤ë¡ÖHealth-related QOL:HRQL¡×¤È¡¢Ä¾ÀܤˤϱƶÁ¤ò¼õ¤±¤Ê¤¤ÈϰϤǤȤ館¤ë¡Önon-health related QOL:NHRQL¡×¤ËÂçÊ̤·¡¢¼ç¤ËÁ°¼Ô¤òÍѤ¤¤¿¼À´µ¡¦¾õÂÖÊ̤μÜÅÙ¤¬³«È¯¤µ¤ì¤Æ¤­¤¿¡£

¤³¤ÎHRQL¤Ï¡¢¤¿¤È¤¨¤ÐÇ¾Â´Ãæ¤Ê¤é·ì°µ¤ä»Í»è¤Îư¤­¤«¤éÆü¾ïÀ¸³èưºî¤ä¼Ò²ñÉüµ¢¤Þ¤Ç¡¢·ò¹¯¾õÂÖ¤òɽ¤¹Â¿¿ô¤Î¹àÌܤò¾Ü¤·¤¯Ä´¤Ù¤ë¤Î¤Ç¡¢ÀâÆÀÎϤ¬¤¢¤ë¡£¤È¤³¤í¤¬¼ÂºÝ¤Ë¤Ï¡¢·ò¹¯¤Î¤¢¤êÊý¤Ï¸å¼Ô¤ÎNHRQL¡¢¤¹¤Ê¤ï¤ÁÃϰè´Ä¶­¤ä·ÐºÑ¾ðÀª¡¢À¯¼£ÂÎÀ©¤È¤¤¤Ã¤¿Í×°ø¤È̵±ï¤Ç¤Ï¤Ê¤¤¡£²¾¤ËHRQL¤Ë¤è¤ë¬ÄêÃͤ¬Æ±¤¸¤Ç¤â¡¢¼£ÎŤμ꤬µÚ¤Ð¤Ê¤¤½ô
Í×°ø¤Ë¤è¤Ã¤Æ¡¢QOL¤Ï°Û¤Ê¤Ã¤Æ¤¯¤ë¤Î¤Ç¤¢¤ë¡£
¡¡
¤³¤Î¤è¤¦¤Ë¡¢QOL¤Ë¤Ï¤¤¤¯¤Ä¤«¤ÎÆñÌ䤬¤Ä¤­¤Þ¤È¤¦¡£¤Þ¤º¡¢²¿¤Ë¤Ä¤¤¤Æ¤Ç¤¢¤ë¤Ë¤»¤è¡¢¡Ö¼Á¡×¤Ï¤½¤â¤½¤â¬ÄꤷÆÀ¤ë¤â¤Î¤Ê¤Î¤«¤È¤¤¤¦ÌäÂ꤬¤¢¤ë¡£Â¬Äê¤È¤Ï¥·¥ó¥×¥ë¤Ë¤¤¤¨¤Ð¿ôÃͲ½¤Ë¤è¤ëµÒ´Ñ²½¤Ç¤¢¤ë¡£¼Á¤Ï¤·¤«¤·¡¢¤½¤ì¤òȽÃǤ¹¤ë¼Ô¤Î²ÁÃʹѤ˱ƶÁ¤µ¤ì¤ë¡£Â¬Äê¤ÏµÒ´Ñ¤À¤¬²ÁÃÍȽÃǤϼç´Ñ¤Ê¤Î¤Ç¡¢QOL¤òÆÍ¤­µÍ¤á¤Æ¹Í¤¨¤ë¤È¡¢¤³¤Î¼ç´Ñ¤ÈµÒ´Ñ¤Î´Ö¤Ç¤â¤¬¤¯¤³¤È¤Ë¤Ê¤ë¡£¤½¤ì¤Ê¤é¡¢¥Ó¥Õ¥©¡¼¡¦¥¢¥Õ¥¿¡¼¤Î¤è¤¦¤Ë¡¢¼ç´ÑÍ×ÁǤò´Þ¤àÁ´Âξõ¶·¤ÎÈæ³Ó¤«¤éQOL¤ò¬¤ì¤Ð¤¤¤¤¤È¤¤¤¦¹Í¤¨¤Ë»ê¤ë¡£¤¹¤ë¤Èº£Å٤ϡ¢QOL¤¬²þÁ±¤·¤Æ¤â¤¤¤ï¤æ¤ë¥ß¥Ë¥Þ¥à¡¦¥ê¥¯¥¥¥ï¥¤¥¢¥á¥ó¥È(minimum requirement=µá¤á¤é¤ì¤ëŬÀڤʿå½à)¤ò³ä¤ê¹þ¤ó¤Ç¤¤¤¿¤é¤É¤¦¤Ê¤Î¤«¤È¤¤¤¦µ¿Ì䤬À¸¤¸¤ë¡£
¡¡
É®¼Ô¤ÎÀìÌç¤Ç¤¢¤ë¥½¡¼¥·¥ã¥ë¥ï¡¼¥¯¤Ç¤Ï¡¢QOL¤ò¸Ä¿Í¤Î¼¡¸µ¤Ç¹Í¤¨¤ë¤ÈƱ»þ¤Ë¡¢½¸ÃĤҤ¤¤Æ¤Ï¼Ò²ñÁ´ÂΤˤª¤±¤ë¿å½à¤Ç¤â¹Í¤¨¤ë¡£¤»¤Ã¤«¤¯¼£ÎŤ¬¸ù¤òÁÕ¤·¤¿¤Î¤Ë»Å»ö¤ä³Ø¹»¡¢Ãϰè¼Ò²ñ¤Ë¼õ¤±Æþ¤ì¤é¤ì¤Ê¤«¤Ã¤¿¤é¤É¤¦¤À¤í¤¦¡£¤¢¤ë¿Í¤¬¼«Ê¬¤ÎQOL¤Ï¹â¤¤¤È¤¤¤¯¤é¼çÄ¥¤·¤Æ¤â¡¢¤½¤Î¾õ¶·¤¬Ã¯¤«¤é¸«¤Æ¤â¿Í´Ö¤Îº¸·¤ò»¤Ê¤¦¤â¤Î¤À¤È¤·¤¿¤é¤É¤¦¤À¤í¤¦¡£Â礲¤µ¤«¤â¤·¤ì¤Ê¤¤¤¬¡¢QOL¤Ë¤Ï¼Ò²ñŪ¸øÀµ¤µ¤ÎÌäÂê¤âÍí¤ó¤Ç¤¯¤ë¡£
¡¡
¤½¤³¤Ç»ä¤¿¤Á¤Ëµá¤á¤é¤ì¤ë¤Î¤Ï¡¢QOL¤È¤¤¤¦³µÇ°¤òÍѤ¤¤ëºÝ¤Ë¤ÏÂоݤȾìÌ̤Ȥò¸ÂÄꤷ¡¢²¿¤òÀâÌÀ¤·¤è¤¦¤È¤·¤Æ¤¤¤ë¤Î¤«¤ò¤Ï¤Ã¤­¤ê¤µ¤»¤Æ¤ª¤¯¤³¤È¤Ç¤¢¤ë¡£QOL¤Ï¡¢µÞ®¤Ë¹âÎ𲽤¬¿Ê¤ß¡¢¿Í¸ý¸º¾¯¤ä·ÐºÑµ¬ÌϤν̾®¤¬É¬»ê¤È¤Ê¤Ã¤¿º£¡¢Èó¾ï¤Ë½ÅÍפʳµÇ°¤Ç¤¢¤ë¡£¤·¤«¤·¡¢¤½¤Î°ÕÌ£¤¹¤ë¤È¤³¤í¤ÎÊñ³çÀ­¤ä¤¢¤¤¤Þ¤¤¤µ¤æ¤¨¤Ë¡¢ÊØÍø¤Ê¼ª¾ã¤ê¤Î¤è¤¤¸ÀÍդȤ·¤ÆÍðÍѤµ¤ì¤ä¤¹¤¤Ì̤⤢¤ë¡£QOL¤Ï¡¢Ãí°Õ¿¼¤¯¡¢À¿¼Â¤ËÍѤ¤¤ë¤è¤¦¤Ë¤·¤¿¤¤¡£
(»²¹Íʸ¸¥) Spilker B. Introduction. In:Spilker B, edited. Quality of Life and pharmacoeconomics in Clinical Trials. New York: Lippincott Williams & Wilkins;1996. Pp.1-10.
 

¤Û¤ê¤³¤·¡¦¤æ¤­¤³
1955ǯ²£ÉÍ»ÔÀ¸¤Þ¤ì¡£¾åÃÒÂç³ØÊ¸³ØÉô¼Ò²ñ³Ø²Ê´¶È¡£¥ë¡¼¥Æ¥ë³Ø±¡Âç³ØÂç³Ø±¡Áí¹ç¿Í´Ö³Ø¸¦µæ²ÊÇî»Î¸å´ü²ÝÄøËþ´üÂà³Ø¡£ÀìÌç¤Ï¥½¡¼¥·¥ã¥ë¥ï¡¼¥¯¡¢ÊÝ·ò°åÎÅÊ¡»ã¡£·ò¹¯²Ê³ØÉô¼Ò²ñÊ¡»ã³Ø²Ê¶µ¼ø¤ò·Ð¤Æ¸½¿¦¡£